Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10331483rdf:typepubmed:Citationlld:pubmed
pubmed-article:10331483lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10331483lifeskim:mentionsumls-concept:C0017007lld:lifeskim
pubmed-article:10331483lifeskim:mentionsumls-concept:C0026691lld:lifeskim
pubmed-article:10331483lifeskim:mentionsumls-concept:C0128897lld:lifeskim
pubmed-article:10331483lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:10331483lifeskim:mentionsumls-concept:C0175630lld:lifeskim
pubmed-article:10331483lifeskim:mentionsumls-concept:C0547047lld:lifeskim
pubmed-article:10331483pubmed:issue5lld:pubmed
pubmed-article:10331483pubmed:dateCreated1999-6-7lld:pubmed
pubmed-article:10331483pubmed:abstractTextKawasaki disease (KD) is a systemic vasculitis preferentially affecting coronary arteries. Extensive monocytes/macrophages infiltrate in the vascular lesions, implying the involvement of a chemotactic cytokine in their recruitment. We investigated the role of monocyte chemoattractant protein-1 (MCP-1, also termed monocyte chemotactic and activating factor) in KD. In the immunohistochemical studies using the cardiac tissues of patients with fatal KD, MCP-1 but not interleukin (IL) -8 or macrophage inflammatory protein-1alpha was localized at the extracellular matrix associated with mononuclear cellular infiltration. The sites of MCP-1 expression correlated with the distribution of the acute inflammation, including early coronary vasculitis. In prospectively studied patients with KD, circulating levels of MCP-1, IL-8, tumor necrosis factor alpha (TNF-alpha), and IL-1alpha were elevated in 73, 77, 57, and 0% of samples before gamma globulin (GG) treatment (400 mg/kg x 5 days = total 2 g/kg), respectively, compared with respective control values. GG treatment correlated with a rapid decrease in the circulating levels of MCP-1 (P = 0.001) but not IL-8 (P = 0.19) or TNF-alpha (P = 0.33). In the sensitive Western blotting, MCP-1 bound to GG. Furthermore, GG inhibited the MCP-1-induced Ca2+ influx in a human monocytic cell line in vitro. These findings suggest a role of MCP-1 in KD, and indicate that GG treatment may block MCP-1 activity, thus alleviating KD vasculitis.lld:pubmed
pubmed-article:10331483pubmed:languageenglld:pubmed
pubmed-article:10331483pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10331483pubmed:citationSubsetIMlld:pubmed
pubmed-article:10331483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10331483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10331483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10331483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10331483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10331483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10331483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10331483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10331483pubmed:statusMEDLINElld:pubmed
pubmed-article:10331483pubmed:monthMaylld:pubmed
pubmed-article:10331483pubmed:issn0741-5400lld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:TatenoSSlld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:HamadaHHlld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:TerashimaYYlld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:TeraoKKlld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:HaradaAAlld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:MatsushimaKKlld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:NiimiHHlld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:YasukawaKKlld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:JibikiTTlld:pubmed
pubmed-article:10331483pubmed:authorpubmed-author:OanaSSlld:pubmed
pubmed-article:10331483pubmed:issnTypePrintlld:pubmed
pubmed-article:10331483pubmed:volume65lld:pubmed
pubmed-article:10331483pubmed:ownerNLMlld:pubmed
pubmed-article:10331483pubmed:authorsCompleteYlld:pubmed
pubmed-article:10331483pubmed:pagination566-72lld:pubmed
pubmed-article:10331483pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:meshHeadingpubmed-meshheading:10331483...lld:pubmed
pubmed-article:10331483pubmed:year1999lld:pubmed
pubmed-article:10331483pubmed:articleTitleDramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment.lld:pubmed
pubmed-article:10331483pubmed:affiliationDepartment of Pediatrics, Chiba University School of Medicine, Chiba-shi, Japan. terai@med.m.chiba-u.ac.jplld:pubmed
pubmed-article:10331483pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10331483pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10331483pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10331483lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10331483lld:pubmed